var data={"title":"Fomepizole: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fomepizole: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6231?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fomepizole-drug-information\" class=\"drug drug_general\">see &quot;Fomepizole: Drug information&quot;</a> and <a href=\"topic.htm?path=fomepizole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fomepizole: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173900\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Antizol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15125571\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Antizol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058824\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Ethylene Glycol Toxicity</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antidote, Methanol Toxicity</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058818\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=fomepizole-drug-information\" class=\"drug drug_general\">see &quot;Fomepizole: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Fomepizole therapy should begin immediately upon suspicion of ethylene glycol or methanol ingestion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Ethylene glycol or methanol toxicity; patient not requiring hemodialysis: </b>Limited data available; consider consultation with a clinical toxicology or poison control center: Infants, Children, and Adolescents: IV: Initial: 15 mg/kg loading dose; followed by 10 mg/kg every 12 hours for 4 doses; then 15 mg/kg every 12 hours until ethylene glycol or methanol concentrations have been reduced to &lt;20 mg/dL and patient is asymptomatic with normal pH (Baum 2000; Benitez 2000; Boyer 2001; Brown 2001; De Brabander 2005; Detaille 2004; Fisher 1998). <b>Note:</b> For severe toxicity requiring concomitant hemodialysis, see Dosage adjustment in renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Ethylene glycol and methanol toxicity:</b> IV: Loading dose of 15 mg/kg should be administered, followed by doses of 10 mg/kg every 12 hours for 4 doses, then 15 mg/kg every 12 hours thereafter until ethylene glycol or methanol concentrations have been reduced to &lt;20 mg/dL and patient is asymptomatic with normal pH. <b>Note:</b> For severe toxicity requiring concomitant hemodialysis, see Dosage adjustment in renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in renal impairment:</b> Infants, Children, Adolescents (Limited data available [Brent 2010]), and Adults: <b>Note:</b> Hemodialysis should be considered as an adjunct to fomepizole in patients with renal failure, significant or worsening metabolic acidosis, or ethylene glycol or methanol concentrations &ge;50 mg/dL. The following dosage adjustments should be used for any patient receiving hemodialysis regardless of renal function</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prior to the start of hemodialysis:</i> To determine if the patient requires a dose of fomepizole at the start of hemodialysis, determine when the last dose was administered.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If &lt;6 hours since last fomepizole dose: Do <b>not</b> administer dose upon beginning dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If &ge;6 hours since last fomepizole dose: Administer next scheduled dose upon beginning dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>During hemodialysis</i>: Administer every 4 hours. Alternatively, a loading dose of 10 to 20 mg/kg followed by a continuous infusion 1 to 1.5 mg/kg/hour during hemodialysis has been described in case reports (Jobard 1996).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Upon completion of hemodialysis; dependent upon the time between the last dose and the end of hemodialysis:</i> To determine if the patient requires a dose of fomepizole at the time of completion of hemodialysis, determine when the last dose was administered.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If &lt;1 hour since last fomepizole dose: Do <b>not</b> administer a dose at the end of hemodialysis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If 1 to 3 hours since last fomepizole dose: Administer <sup>1</sup>/<sub>2</sub> of the next scheduled dose at the end of hemodialysis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If &gt;3 hours since last fomepizole dose: Administer the next scheduled dose at the end of hemodialysis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance dose off hemodialysis</i>: Administer every 12 hours starting from the time last dose administered</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in hepatic impairment:</b> Fomepizole is metabolized in the liver. Specific dosage adjustments have not been determined in patients with hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173877\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Antizol: 1 g/mL (1.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g/mL (1.5 mL); 1.5 g/1.5 mL (1.5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173863\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058829\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: IV: Infuse as a diluted solution over 30 minutes; rapid infusion at a concentration of 25 mg/mL has been associated with vein irritation and phlebosclerosis. Fomepizole turns to a solid at temperatures less than 25&deg;C (77&deg;F); if the solution has solidified, the solution should be liquefied by running the vial under warm water or by holding in the hand; the efficacy, safety, or stability is not affected by solidification.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173895\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at controlled room temperature, 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); fomepizole solidifies at temperatures &lt;25&deg;C (77&deg;F). If solution becomes solid in the vial, it be should be carefully warmed by running the vial under warm water or by holding in the hand. Solidification does not affect the efficacy, safety, or stability of the drug. Diluted solution should be used within 24 hours and may be stored at room temperature or under refrigeration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058828\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Antidote for ethylene glycol (antifreeze) or methanol toxicity; may be useful in propylene glycol toxicity (FDA approved in ages &ge;18 years)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7914140\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Fomepizole may be confused with omeprazole</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173925\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, facial flushing, hypotension, phlebitis, shock, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation, altered sense of smell, anxiety, dizziness, drowsiness, headache, metallic taste, seizure, speech disturbance, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, decreased appetite, diarrhea, heartburn, hiccups, nausea, unpleasant taste, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Anuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, disseminated intravascular coagulation (DIC), eosinophilia, lymphangitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased liver enzymes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Application site reaction, inflammation at injection site, pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Back pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Nystagmus, transient blurred vision, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Pharyngitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, multi-organ failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Hypersensitivity reaction (mild; mild rash, eosinophilia)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173883\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to fomepizole, other pyrazoles, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173867\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; metabolized in the liver.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; fomepizole and its metabolites are excreted in the urine. Hemodialysis should be considered as an adjunct to fomepizole in patients with renal failure, significant acidosis (pH &lt;7.25-7.3), worsening metabolic acidosis, or ethylene glycol or methanol concentrations &ge;50 mg/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Pediatric administration is not FDA approved; however, safe and efficacious use in this patient population for ethylene glycol and methanol intoxication has been reported (Baum, 2000; Benitez, 2000; Boyer, 2001; Brown, 2001; De Brabander, 2005; Detaille, 2004; Fisher, 1998).  Consider consultation with a clinical toxicologist or poison control center. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: Should not be given undiluted or by bolus injection. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299362\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6220494\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13323&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173897\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Ethanol decreases the rate of fomepizole elimination by ~50%; conversely, fomepizole decreases the rate of elimination of ethanol by ~40%.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173873\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173886\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey, 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058823\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Vital signs, arterial blood gases, acid-base status, renal function (BUN, creatinine, and urinalysis), liver function, WBC counts, anion and osmolar gaps, clinical signs and symptoms of toxicity (arrhythmias, seizures, coma); urinary oxalate, serum and urinary ethylene glycol or serum methanol level depending upon the agent ingested; formic acid level (methanol ingestion)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058827\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Ethylene glycol or methanol serum concentration: Goal: &lt;20 mg/dL; therapeutic plasma fomepizole level: 0.8 mcg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173866\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Fomepizole competitively inhibits alcohol dehydrogenase, an enzyme which catalyzes the metabolism of ethanol, ethylene glycol, and methanol to their toxic metabolites. Ethylene glycol is metabolized to glycoaldehyde, then oxidized to glycolate, glyoxylate, and oxalate. Glycolate and oxalate are responsible for metabolic acidosis and renal damage. Methanol is metabolized to formaldehyde, then oxidized to formic acid. Formic acid is responsible for metabolic acidosis and visual disturbances.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173882\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of effect: Peak effect: Maximum: 1.5-2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Readily absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 0.6-1.02 L/kg; rapidly into total body water </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Negligible </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to 4-carboxypyrazole (80% to 85% of dose), 4-hydroxymethylpyrazole, and their N-glucuronide conjugates; following multiple doses, induces its own metabolism via CYP oxidases after 30-40 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Has not been calculated; varies with dose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (1% to 3.5% as unchanged drug and metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323159\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Antizol Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/mL (1.5 mL): $1,849.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Fomepizole Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/mL (1.5 mL): $1,290.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038622\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Antizol (GB, IE);</li>\n      <li>FomepizoleAP-HP (FR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Antizol (fomepizole injection) [prescribing information]. Dover, DE: Paladin Labs (USA) Inc.; April 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baum CR, Langman CB, Oker EE, et al, &ldquo;Fomepizole Treatment of Ethylene Glycol Poisoning in an Infant,&rdquo; <i>Pediatrics</i>, 2000, 106(6):1489-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/11099610/pubmed\" target=\"_blank\" id=\"11099610\">11099610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benitez JG, Swanson-Biearman B, and Krenzelok EP, &ldquo;Nystagmus Secondary to Fomepizole Administration in a Pediatric Patient,&rdquo; <i>J Toxicol Clin Toxicol</i>, 2000, 38(7):795-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/11192468/pubmed\" target=\"_blank\" id=\"11192468\">11192468</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boyer EW, Mejia M, Woolf A, et al, &ldquo;Severe Ethylene Glycol Ingestion Treated Without Hemodialysis,&rdquo; <i>Pediatrics</i>, 2001, 107(1):172-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/11134452/pubmed\" target=\"_blank\" id=\"11134452\">11134452</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brent J. Fomepizole for the treatment of pediatric ethylene and diethylene glycol, butoxyethanol, and methanol poisonings. <i>Clin Toxicol (Phila)</i>. 2010;48(5):401-406.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/20586570/pubmed\" target=\"_blank\" id=\"20586570\">20586570</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brown MJ, Shannon MW, Woolf A, et al, &ldquo;Childhood Methanol Ingestion Treated With Fomepizole and Hemodialysis,&rdquo; <i>Pediatrics</i>, 2001, 108(4):e77-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/11581485/pubmed\" target=\"_blank\" id=\"11581485\">11581485</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Calello DP, Osterhoudt KC, Henretig FM. New and novel antidotes in pediatrics. <i>Pediatr Emerg Care</i>. 2006;22(7):523-530. Erratum in intravenous n-acetylcysteine dosing [<i>Pediatr Emerg Care</i>. 2007].<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/16871118/pubmed\" target=\"_blank\" id=\"16871118\">16871118</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Casavant MJ. Fomepizole in the treatment of poisoning. <i>Pediatrics</i>. 2001;107(1):170.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/11134450/pubmed\" target=\"_blank\" id=\"11134450\">11134450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chen TH, Kuo CH, Huang CT, Wang WL. Use of fomepizole in pediatric methanol exposure: the first case report in Taiwan and a literature review. <i>Pediatr Neonatol</i>. 2016;57(4):351-354<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/24332660/pubmed\" target=\"_blank\" id=\"24332660\">24332660</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dart RC, Goldfrank LR, Chyka PA, et al. Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. <i>Ann Emerg Med</i>. 2000;36(2):126-132.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/10918103/pubmed\" target=\"_blank\" id=\"10918103\">10918103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Brabander N, Wojciechowski M, De Decker K, et al, &ldquo;Fomepizole as a Therapeutic Strategy in Paediatric Methanol Poisoning: A Case Report and Review of the Literature,&rdquo; <i>Eur J Pediatr</i>, 2005, 164(3):158-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/15578220/pubmed\" target=\"_blank\" id=\"15578220\">15578220</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Detaille T, Wallemacq P, Clement de Clety S, et al, &ldquo;Fomepizole Alone for Severe Infant Ethylene Glycol Poisoning,&rdquo; <i>Pediatr Crit Care Med</i>, 2004, 5(5):490-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/15329167/pubmed\" target=\"_blank\" id=\"15329167\">15329167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Druteika DP, Zed PJ, and Ensom MH, &ldquo;Role of Fomepizole in the Management of Ethylene Glycol Toxicity,&rdquo; <i>Pharmacotherapy</i>, 2002, 22(3):365-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/11899949/pubmed\" target=\"_blank\" id=\"11899949\">11899949</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fisher DM and Diaz JE, &ldquo;Pediatric Methanol Poisoning Treated With Fomepizole (Antizol&reg;),&rdquo; <i>J Toxicol Clin Toxicol</i>, 1998, 36:512.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hann G, Duncan D, Sudhir G, West P, Sohi D. Antifreeze on a freezing morning: ethylene glycol poisoning in a 2-year-old. <i>BMJ Case Rep</i>. 2012;27:2012<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/22605809/pubmed\" target=\"_blank\" id=\"22605809\">22605809</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang GS, Yin S, Shear B, Heard K. Severe poisoning after accidental pediatric ingestion of glycol ethers. <i>Pediatrics</i>. 2012;130(4):e1026-1029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/23008459/pubmed\" target=\"_blank\" id=\"23008459\">23008459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    White ML, Liebelt EL. Update on antidotes for pediatric poisoning. <i>Pediatr Emerg Care</i>. 2006;22(11):740-746.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/17110870/pubmed\" target=\"_blank\" id=\"17110870\">17110870</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13323 Version 80.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F173900\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F15125571\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1058824\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1058818\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F173877\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F173863\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1058829\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F173895\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1058828\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7914140\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F173925\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F173883\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F173867\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299362\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6220494\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F173897\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F173873\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F173886\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1058823\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1058827\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F173866\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F173882\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323159\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038622\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13323|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fomepizole-drug-information\" class=\"drug drug_general\">Fomepizole: Drug information</a></li><li><a href=\"topic.htm?path=fomepizole-patient-drug-information\" class=\"drug drug_patient\">Fomepizole: Patient drug information</a></li></ul></div></div>","javascript":null}